“How much alpha-lipoic acid should I take” is a question for your clinician; “how much did the studies use, and when did participants take it” is a question an article can answer, and the answer is more specific than most labels suggest.
Quick answer: The oral dose used in most of the positive human trials was 600 mg per day of racemic alpha-lipoic acid, usually taken once in the morning on an empty stomach, 30 to 60 minutes before breakfast. Blood sugar and insulin sensitivity trials ranged from 300 to 1,200 mg daily, sometimes split into two or three doses. Higher amounts produced more nausea without clearly more benefit. None of this is a dosing instruction; the right amount for you, if any, depends on your medications and labs.
Why the timing question is not trivial for ALA
Two features of alpha-lipoic acid (ALA) make timing matter more than it does for many supplements.
First, oral absorption is poor and food makes it worse. Pharmacokinetic studies estimate that only about 30 percent of an oral dose reaches the bloodstream, and taking it with a meal can cut that further. That is why trial protocols almost uniformly instructed participants to take it before breakfast or at least a couple of hours away from food.
Second, it leaves the blood fast. ALA has a plasma half-life of roughly 30 minutes to an hour. Peak levels occur within about an hour of an empty-stomach dose and are largely gone within a few hours. Whatever ALA does inside cells may outlast its blood levels, but a single morning dose does not maintain a steady concentration all day. This is part of why researchers have debated whether divided dosing makes more sense. The ALA and blood sugar article discusses how this may explain the gap between fasting glucose results and A1C results.
What the neuropathy trials used
The clearest dose-finding data comes from the neuropathy research, covered in depth in ALA and diabetic neuropathy. A five-week oral trial compared 600, 1,200, and 1,800 mg daily against placebo in roughly 180 people. All three doses outperformed placebo on symptom scores; the two higher doses added nausea and vomiting without adding much benefit. That is where the 600 mg once-daily figure comes from. The four-year progression trial and most subsequent oral neuropathy studies adopted 600 mg once daily, taken before breakfast.
The intravenous trials, which gave 600 mg daily for about three weeks, are a medical procedure with different absorption and are not a model for oral dosing.
What the blood sugar and insulin sensitivity trials used
This literature is messier. Doses ranged from 300 mg to 1,200 mg daily, and a few studies went higher. Some used a single morning dose; others split it into two or three doses with meals, which trades absorption for convenience and smoother blood levels. Durations ran from four weeks to six months, with most under three months.
Meta-analyses have not found a clean dose-response relationship, meaning more milligrams did not reliably produce bigger changes in fasting glucose or HOMA-IR. That may reflect the small sample sizes, the variety of populations studied, or a real plateau. Either way, it undercuts the assumption that if 600 mg is good, 1,200 mg is twice as good. You can check the primary trials through a PubMed search for ALA dose and insulin sensitivity. If HOMA-IR is unfamiliar, the HOMA-IR calculator explains what the number represents.
Racemic versus R-ALA changes the milligram math
All the doses above refer to racemic ALA, the standard 50/50 mixture. Stabilized R-ALA products reach higher blood levels per milligram, which has led sellers to suggest that a smaller R-ALA dose is “equivalent” to 600 mg racemic. That is an absorption estimate, not a clinical finding, and no adequately sized trial has tested it. R-ALA vs. regular alpha-lipoic acid walks through the evidence. If you use an R-ALA product, the trial doses do not map onto it directly, which is one more reason the specific amount belongs in a conversation with a pharmacist or prescriber.
Timing details from the protocols
A few patterns show up repeatedly in trial methods sections and are worth knowing, not as instructions but as context for what the results actually reflect.
Empty stomach, morning. The most common protocol was 600 mg taken 30 minutes before breakfast with water. Some protocols said “at least two hours after a meal” instead.
Consistency over days. Participants took it daily for the full study period. There is no evidence for intermittent or “as needed” use for any outcome.
Divided doses for higher totals. Studies using 1,200 mg or more typically split it, often 600 mg twice daily, to reduce nausea.
Duration before measuring. Neuropathy symptom changes were measured at three to five weeks. Glucose and insulin markers were usually measured at eight to twelve weeks. A1C needs roughly three months to reflect a change, and many trials were too short for that. The A1C and glucose guide explains why.
The stomach upset that some people experience on an empty stomach creates a real tradeoff: taking it with food reduces nausea and also reduces absorption. Trial participants who had trouble were sometimes moved to a with-food schedule. Whether that compromise is worth it is an individual question.
How to read the dose on a label
Check the serving size. “600 mg per serving” may mean two 300 mg capsules, which matters if you are trying to match a once-daily protocol. Check the form: a label that says “R-ALA” or “sodium R-lipoate” is not the same milligram-for-milligram as racemic. Check for a third-party testing seal. Metabolic Clarity Labs sells berberine, not ALA, and the same label scrutiny applies to any MCL product. For a side-by-side look at how dosing was studied for other supplements in this space, the supplements for metabolic syndrome hub has a section for each.
Safety at the doses studied
At 600 mg daily, trial side effects were mainly mild nausea and stomach upset; at 1,200 mg and above they became more common. Rare but serious issues, including insulin autoimmune syndrome and effects on thyroid hormone, are covered in ALA side effects and interactions.
Hypoglycemia warning: Combining any blood-sugar-active supplement with insulin, sulfonylureas, or other glucose-lowering medicines can push glucose too low. Symptoms include shakiness, sweating, confusion, and a fast heartbeat. Do not add a supplement to a medication plan without your prescriber’s knowledge.
Timing interacts with these concerns directly: an empty-stomach morning dose of ALA lands at the same time many people take levothyroxine (which also needs an empty stomach) and morning diabetes medicines. Separating ALA from levothyroxine by several hours and discussing morning glucose medicines with your prescriber are the concrete steps. Oncologists generally ask that ALA be stopped during chemotherapy or radiation. The MedlinePlus alpha-lipoic acid entry is a maintained reference for these interactions.
Questions to bring to your appointment
- I take levothyroxine (or another empty-stomach morning medicine). If I tried ALA before breakfast, how would we schedule both?
- Which of my glucose medicines could interact with a morning ALA dose, and what morning or overnight readings would be a signal to stop?
- If the goal is insulin sensitivity rather than nerve symptoms, is there any reason to think a split dose would matter for me?
- If I tried 600 mg daily, which labs would you check at the start and at twelve weeks, and what change would be worth continuing for?
- If I get nausea on an empty stomach, would you rather I take it with food, lower the amount, or stop?
- Is there a reason to prioritize this over addressing sleep, movement, or the food pattern we discussed, which have much larger trials behind them?
The trial protocols are consistent enough that “600 mg once daily before breakfast” is a fair summary of what was studied. Whether any of it should apply to you is the part no article can decide, and the insulin resistance guide is a better place to start than a supplement bottle.
About the author: Charles Kirkland is the founder of Metabolic Clarity Labs and author of The Journey Back. He is not a physician. This is general education, not a medically reviewed treatment plan.
Sources checked October 29, 2026. Discuss personal decisions with a qualified clinician or pharmacist. Do not start, stop, or change prescribed treatment based on this article.
Leave a Reply